BioCentury | Aug 2, 2019
Finance

Earnings on deck

...NYSE:AMRX) 8/8 Pre $0.14 $0.24 -42% Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) 8/8 Pre $0.83 $0.95 -13% Pacira Pharmaceuticals Inc....
BioCentury | May 1, 2019
Company News

May 1 Company Quick Takes: Heron, Nabriva, Allergan, GSK, Merck, Alnylam

...information for the long-acting formulation of bupivacaine in a fixed-dose combination with meloxicam. Shares of Pacira Pharmaceuticals Inc....
BioCentury | Feb 22, 2019
Finance

Earnings on deck

...NASDAQ:EGRX) 2/28 Pre $1.16 $1.00 16% Endo International plc (NASDAQ:ENDP) 2/28 Pre $0.59 $0.77 -23% Pacira Pharmaceuticals Inc....
BioCentury | Dec 8, 2018
Regulation

Path to opioid-free pain relief

...or 72 hours after surgery. The label for Exparel bupivacaine, an extended-release liposomal formulation from Pacira Pharmaceuticals Inc....
...use in trials, but notes "the clinical relevance of these data has not been demonstrated." Pacira Pharmaceuticals Inc....
...the potential for a product like Zilretta to directly contribute to the solution,” he said. Pacira Pharmaceuticals Inc....
BioCentury | Nov 2, 2018
Politics & Policy

CMS rule cuts reimbursement for new Part B drugs

...through one all-inclusive bundled payment. The rule will go into effect on Jan. 1, 2019. Pacira Pharmaceuticals Inc....
...rather than ASP plus 6%. The rule will take effect Jan. 1, 2020. Mary Romeo Exparel, bupivacaine (depobupivacaine) CMS Pacira Pharmaceuticals Inc....
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of therapy Pacira Pharmaceuticals Inc....
BioCentury | Jun 29, 2018
Financial News

C-Bridge leads Nuance's series B

...South Africa (see "East by South" ). Earlier this month, Nuance gained exclusive rights from Pacira Pharmaceuticals Inc....
...and commercialize Exparel bupivacaine in China -- a deal Nuance said was facilitated by C-Bridge. Pacira...
BioCentury | Jun 28, 2018
Financial News

C-Bridge leads Nuance's series B

...South Africa (see "East by South" ). Earlier this month, Nuance gained exclusive rights from Pacira Pharmaceuticals Inc....
...and commercialize Exparel bupivacaine in China -- a deal Nuance said was facilitated by C-Bridge. Pacira...
BioCentury | Jun 26, 2018
Company News

Nuance gains Chinese rights to Pacira's Exparel

...Biotech Co. Ltd. (Shanghai, China) exclusive rights to develop and commercialize Exparel bupivacaine in China. Pacira...
...up front and is eligible for $55 million in regulatory and sales milestones, plus royalties. Pacira's...
...an application with China's State Drug Administration this year seeking approval to begin clinical trials. Pacira...
BioCentury | Apr 13, 2018
Clinical News

FDA approves Pacira's sNDA for Exparel

...surgeries. In February, an FDA advisory committee voted 6-4 against approval of the sNDA, which Pacira...
...resubmitted following receipt of a complete response letter in 2015. The CRL said that while Pacira...
...as a femoral nerve block in lower extremity surgeries (see BioCentury, July 28, 2017) . Pacira...
Items per page:
1 - 10 of 156
BioCentury | Aug 2, 2019
Finance

Earnings on deck

...NYSE:AMRX) 8/8 Pre $0.14 $0.24 -42% Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) 8/8 Pre $0.83 $0.95 -13% Pacira Pharmaceuticals Inc....
BioCentury | May 1, 2019
Company News

May 1 Company Quick Takes: Heron, Nabriva, Allergan, GSK, Merck, Alnylam

...information for the long-acting formulation of bupivacaine in a fixed-dose combination with meloxicam. Shares of Pacira Pharmaceuticals Inc....
BioCentury | Feb 22, 2019
Finance

Earnings on deck

...NASDAQ:EGRX) 2/28 Pre $1.16 $1.00 16% Endo International plc (NASDAQ:ENDP) 2/28 Pre $0.59 $0.77 -23% Pacira Pharmaceuticals Inc....
BioCentury | Dec 8, 2018
Regulation

Path to opioid-free pain relief

...or 72 hours after surgery. The label for Exparel bupivacaine, an extended-release liposomal formulation from Pacira Pharmaceuticals Inc....
...use in trials, but notes "the clinical relevance of these data has not been demonstrated." Pacira Pharmaceuticals Inc....
...the potential for a product like Zilretta to directly contribute to the solution,” he said. Pacira Pharmaceuticals Inc....
BioCentury | Nov 2, 2018
Politics & Policy

CMS rule cuts reimbursement for new Part B drugs

...through one all-inclusive bundled payment. The rule will go into effect on Jan. 1, 2019. Pacira Pharmaceuticals Inc....
...rather than ASP plus 6%. The rule will take effect Jan. 1, 2020. Mary Romeo Exparel, bupivacaine (depobupivacaine) CMS Pacira Pharmaceuticals Inc....
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of therapy Pacira Pharmaceuticals Inc....
BioCentury | Jun 29, 2018
Financial News

C-Bridge leads Nuance's series B

...South Africa (see "East by South" ). Earlier this month, Nuance gained exclusive rights from Pacira Pharmaceuticals Inc....
...and commercialize Exparel bupivacaine in China -- a deal Nuance said was facilitated by C-Bridge. Pacira...
BioCentury | Jun 28, 2018
Financial News

C-Bridge leads Nuance's series B

...South Africa (see "East by South" ). Earlier this month, Nuance gained exclusive rights from Pacira Pharmaceuticals Inc....
...and commercialize Exparel bupivacaine in China -- a deal Nuance said was facilitated by C-Bridge. Pacira...
BioCentury | Jun 26, 2018
Company News

Nuance gains Chinese rights to Pacira's Exparel

...Biotech Co. Ltd. (Shanghai, China) exclusive rights to develop and commercialize Exparel bupivacaine in China. Pacira...
...up front and is eligible for $55 million in regulatory and sales milestones, plus royalties. Pacira's...
...an application with China's State Drug Administration this year seeking approval to begin clinical trials. Pacira...
BioCentury | Apr 13, 2018
Clinical News

FDA approves Pacira's sNDA for Exparel

...surgeries. In February, an FDA advisory committee voted 6-4 against approval of the sNDA, which Pacira...
...resubmitted following receipt of a complete response letter in 2015. The CRL said that while Pacira...
...as a femoral nerve block in lower extremity surgeries (see BioCentury, July 28, 2017) . Pacira...
Items per page:
1 - 10 of 156